A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

被引：151

作者：

Byrne, Hannah ^{[1
]}

Conroy, Paul J. ^{[2
]}

Whisstock, James C. ^{[2
]}

O'Kennedy, Richard J. ^{[1
,3
]}

机构：

[1] Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland

[2] Monash Univ, Dept Biochem & Mol Biol, Fac Med Nursing & Hlth Sci, Melbourne, Vic 3800, Australia

[3] Dublin City Univ, Biomed Diagnost Inst, Natl Ctr Sensor Res, Dublin 9, Ireland

来源：

TRENDS IN BIOTECHNOLOGY | 2013年 / 31卷 / 11期

基金：

澳大利亚研究理事会; 爱尔兰科学基金会; 英国医学研究理事会;

关键词：

SINGLE-CHAIN ANTIBODY; GROWTH-FACTOR RECEPTOR; CELL LYMPHOMA XENOGRAFTS; CD19 X CD3; CHRONIC LYMPHOCYTIC-LEUKEMIA; EXPRESSING TUMOR-CELLS; CANCER-IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; ANTIGEN-BINDING; GENE-TRANSFER;

D O I：

10.1016/j.tibtech.2013.08.007

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Artificial manipulation of antibody genes has facilitated the production of several unique recombinant antibody formats, which have highly important therapeutic and biotechnological applications. Although bispecific antibodies (bsAbs) are not new, they are coming to the forefront as our knowledge of the potential efficacy of antibody-based therapeutics expands. The next generation of bsAbs is developing due to significant improvements in recombinant antibody technologies. This review focuses on recent advances with a particular focus on improvements in format and design that are contributing to the resurgence of bsAbs, and in particular, on innovative structures applicable to next generation point-of-care (POC) devices with applicability to low resource environments.

引用

页码：621 / 632

页数：12

共 142 条

[1]

[Anonymous], 2012, Global Tuberculosis Report

[2]

Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody [J].

Asano, Ryutaro ;

Kumagai, Takashi ;

Nagai, Keisuke ;

Taki, Shintaro ;

Shimomura, Ippei ;

Arai, Kyoko ;

Ogata, Hiromi ;

Okada, Mai ;

Hayasaka, Fumitaka ;

Sanada, Hideaki ;

Nakanishi, Takeshi ;

Karvonen, Teemu ;

Hayashi, Hiroki ;

Katayose, Yu ;

Unno, Michiaki ;

Kudo, Toshio ;

Umetsu, Mitsuo ;

Kumagai, Izumi .

PROTEIN ENGINEERING DESIGN & SELECTION, 2013, 26 (05) :359-367

[3]

Antibody production [J].

Birch, John R. ;

Racher, Andrew J. .

ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (5-6) :671-685

[4]

CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation [J].

Brandao, JG ;

Scheper, RJ ;

Lougheed, SM ;

Curiel, DT ;

Tillman, BW ;

Gerritsen, WR ;

van den Eertwegh, AJM ;

Pinedo, HM ;

Haisma, HJ ;

de Gruijl, TD .

VACCINE, 2003, 21 (19-20) :2268-2272

[5]

MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors [J].

Brischwein, K ;

Schlereth, B ;

Guller, B ;

Steiger, C ;

Wolf, A ;

Lutterbuese, R ;

Offner, S ;

Locher, M ;

Urbig, T ;

Raum, T ;

Kleindienst, P ;

Wimberger, P ;

Kimmig, R ;

Fichtner, I ;

Kufer, P ;

Hofmeister, R ;

da Silva, AJ ;

Baeuerle, PA .

MOLECULAR IMMUNOLOGY, 2006, 43 (08) :1129-1143

[6]

A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells [J].

Bruenke, J ;

Fischer, B ;

Barbin, K ;

Schreiter, K ;

Wachter, Y ;

Mahr, K ;

Titgemeyer, F ;

Niederweis, M ;

Peipp, M ;

Zunino, SJ ;

Repp, R ;

Valerius, T ;

Fey, GH .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) :167-179

[7]

Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins:: A new strategy in the treatment of chronic inflammatory diseases and HIV [J].

Brühl, H ;

Cihak, J ;

Stangassinger, M ;

Schlöndorff, D ;

Mack, M .

JOURNAL OF IMMUNOLOGY, 2001, 166 (04) :2420-2426

[8]

Brüsselbach S, 1999, TUMOR TARGET, V4, P115

[9]

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells [J].

Buehler, P. ;

Wolf, P. ;

Gierschner, D. ;

Schaber, I. ;

Katzenwadel, A. ;

Schultze-Seemann, W. ;

Wetterauer, U. ;

Tacke, M. ;

Swamy, M. ;

Schamel, W. W. A. ;

Elsaesser-Beile, U. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (01) :43-52

[10]

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion [J].

Buhmann, R. ;

Simoes, B. ;

Stanglmaier, M. ;

Yang, T. ;

Faltin, M. ;

Bund, D. ;

Lindhofer, H. ;

Kolb, H-J .

BONE MARROW TRANSPLANTATION, 2009, 43 (05) :383-397

← 1 2 3 4 5 6 7 8 9 10 →